City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  35  Clinical trial(s) found  (Page 1 of 2 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 14011 ClinicalTrials.gov Number: NCT02142049

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Multicenter Study of Ibrutinib and Lenalidomide in Combination with DA-EPOCH-R in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma

COH Protocol Number: 13431 ClinicalTrials.gov Number: NCT01868022

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling

COH Protocol Number: 13355 ClinicalTrials.gov Number: NCT02041481

Principal Investigator: Marwan Fakih, MD
Sponsor: Institutional

Title:  A Phase I Clinical Trial of MEK162 in Combination with FOLFOX in Patients with Advanced Metastatic Colorectal Cancer Who Failed Prior Standard Therapy

COH Protocol Number: 13331 ClinicalTrials.gov Number: NCT01907802

Principal Investigator: Vincent Chung, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-73, NCI # 9343: A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients with BRAF V600X Mutations and Renal or Hepatic Dysfunction

COH Protocol Number: 13277 ClinicalTrials.gov Number: NCT02051257

Principal Investigator: Leslie Popplewell, MD
Sponsor: NCI Approved External Peer Review

Title:  Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

COH Protocol Number: 13257 ClinicalTrials.gov Number: NCT01923506

Principal Investigator: Sagus Sampath, MD
Sponsor: Institutional

Title:  Stereotactic Body Radiation Therapy to the Prostate Fossa: Phase I Dose Escalation Study

COH Protocol Number: 13242 ClinicalTrials.gov Number: NCT01877811

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients with Advanced Solid Tumors in Phase 1 and in Patients with Advanced Melanoma and Metastatic Colorectal Cancer with BRAF Mutation in Phase 2

COH Protocol Number: 13190 ClinicalTrials.gov Number: NCT01789242

Principal Investigator: Michael Rosenzweig, MD
Sponsor: Industrial

Title:  A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

COH Protocol Number: 13175 ClinicalTrials.gov Number: NCT01902329

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase I Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia

COH Protocol Number: 13167 ClinicalTrials.gov Number: NCT01363297

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  An Open-Label, Phase 1/2 Study of Inotuzumab Ozogamicin in Subjects With Relapsed or Refractory CD22-Positive Acute Lymphocytic Leukemia

COH Protocol Number: 13116 ClinicalTrials.gov Number: NCT01156584

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  A Phase I Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients with Recurrent High Grade Glioma

COH Protocol Number: 13105 ClinicalTrials.gov Number: NCT01208051

Principal Investigator: Dean Lim, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-127, NCI# 8317: Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer

COH Protocol Number: 12415 ClinicalTrials.gov Number: NCT01892293

Principal Investigator: Myo Htut, MD
Sponsor: Industrial

Title:  A Phase I/IIa Open Label, Multiple Site Clinical Trial Evaluating the Safety and Activity of Engineered Autologous T Cells Expressing an Affinity-Enhanced TCR Specific for NY-ESO-1 and LAGE-1, in Patients with Relapsed or Progressive Disease in Multiple Myeloma

COH Protocol Number: 12398 ClinicalTrials.gov Number: NCT01874288

Principal Investigator: Ryotaro Nakamura, MD
Sponsor: Industrial

Title:  A Phase I/II Study of De-Immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients with B-Cell Non-Hodgkin Lymphoma (NHL)

COH Protocol Number: 12384 ClinicalTrials.gov Number: NCT01668719

Principal Investigator: Michael Rosenzweig, MD
Sponsor: Cooperative Group

Title:  SWOG S1211: A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

COH Protocol Number: 12293 ClinicalTrials.gov Number: NCT01837667

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination with Docetaxel in the Treatment of Patients with Advanced Solid Tumors

COH Protocol Number: 12291 ClinicalTrials.gov Number: NCT01567891

Principal Investigator: Mihaela Cristea, MD
Sponsor: Industrial

Title:  A Phase I/IIa, Open Label, Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1/LAGE-1 in Patients with Recurrent or Treatment Refractory Ovarian Cancer

COH Protocol Number: 12267 ClinicalTrials.gov Number: NCT02119468

Principal Investigator: Amrita Krishnan, MD
Sponsor: Institutional

Title:  Phase I/II Trial of MLN9708 plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma

COH Protocol Number: 12260 ClinicalTrials.gov Number: NCT01729806

Principal Investigator: Leslie Popplewell, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-69, NCI #9197: A Phase I study of Ipilimumab in Combination with Rituximab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

COH Protocol Number: 12223 ClinicalTrials.gov Number: NCT01795924

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  An Open-Label, Phase 1/2 Study of PD-616 and Low-dose Cytarabine in Patients with Untreated or Relapsed/Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

COH Protocol Number: 12219 ClinicalTrials.gov Number: NCT01723800

Principal Investigator: Karen Reckamp, MD
Sponsor: Institutional

Title:  Phase I Trial of BKM120 in Combination with Carboplatin and Pemetrexed in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 12217 ClinicalTrials.gov Number: NCT01638533

Principal Investigator: Vincent Chung, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-72, NCI #9008: A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

COH Protocol Number: 12214 ClinicalTrials.gov Number: NCT01786096

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients with B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas

COH Protocol Number: 12089 ClinicalTrials.gov Number: NCT01654965

Principal Investigator: Marianna Koczywas, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-68, NCI #9152: A Phase I Study of ARQ 197 in Combination with IV Topotecan in Advanced Solid Tumors with an Expansion Cohort in Small Cell Lung Cancer

COH Protocol Number: 12063 ClinicalTrials.gov Number: NCT01520558

Principal Investigator: Amandeep Salhotra, MD
Sponsor: Industrial

Title:  A Phase I/II Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.